Volume 65, Issue 2, Pages (February 2004)

Slides:

Advertisements

Similar presentations

Date of download: 9/17/2016 From: Dose Response to Vitamin D Supplementation in Postmenopausal Women: A Randomized Trial Ann Intern Med. 2012;156(6):

Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 67, Pages S1-S7 (June 2005)

Impact of Metabolic Syndrome on Graft Function and Survival After Cadaveric Renal Transplantation Esteban Porrini, MD, Patricia Delgado, MD, Celia Bigo,

Volume 73, Issue 1, Pages 3-5 (January 2008)

Renal vitamin D receptor expression and vitamin D renoprotection

Volume 75, Issue 3, Pages (February 2009)

FGF23 or PTH: which comes first in CKD ?

Vitamin D deficiency and heart disease

Tilman B. Drüeke, Ziad A. Massy Kidney International

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Continuous renal replacement therapy in the critically ill patient

Volume 63, Pages S88-S90 (June 2003)

Section 5: Dialysis Interventions for Treatment of AKI

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Volume 76, Pages S50-S99 (August 2009)

Volume 66, Issue 5, Pages (November 2004)

A new era in phosphate binder therapy: What are the options?

Volume 79, Pages S20-S23 (April 2011)

The need for reliable serum parathyroid hormone measurements

New vitamin D analogs Kidney International

Use of vitamin D in chronic kidney disease patients

Stephen P. McDonald Kidney International Supplements

Volume 87, Issue 2, Pages (February 2015)

Florian Lang, Michael Föller Kidney International

Volume 71, Issue 11, Pages (June 2007)

Volume 79, Issue 1, Pages (January 2011)

Volume 54, Issue 3, Pages (September 1998)

Volume 69, Issue 3, Pages (February 2006)

Vitamin D receptor: A highly versatile nuclear receptor

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

Volume 70, Issue 12, Pages (December 2006)

Volume 63, Pages S115-S118 (June 2003)

Role of vitamin D receptor activators on cardiovascular risk

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 3, Pages (March 2015)

Calcium sensing in podocytes

Volume 63, Issue 2, Pages (February 2003)

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 54, Pages S135-S139 (December 1998)

Volume 78, Issue 4, Pages (August 2010)

Fibroblast growth factor 23: the making of a hormone

Volume 56, Issue 4, Pages (October 1999)

Volume 56, Issue 3, Pages (September 1999)

Latest findings in phosphate homeostasis

Volume 63, Pages S79-S82 (June 2003)

Organ transplantation goes to the movies

Does equal care give equal outcomes?

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 80, Issue 10, Pages (November 2011)

Volume 63, Issue 6, Pages (June 2003)

Is complement a target for therapy in renal disease?

Volume 68, Issue 2, Pages (August 2005)

Stephen G. Rostand, Tilman B. Drüeke Kidney International

Recent developments in the management of secondary hyperparathyroidism

Volume 70, Issue 5, Pages (September 2006)

Volume 56, Issue 1, Pages (July 1999)

The international realities of live donor kidney transplantation

Volume 54, Issue 6, Pages (January 1998)

Increased fetuin-A levels following treatment with a vitamin D analog

The ins and outs of phosphate homeostasis

Control of uremic bone disease: Role of vitamin D analogs

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 57, Issue 2, Pages (October 2000)

Volume 54, Pages S112-S119 (December 1998)

Ronen Levi, Justin Silver Kidney International

Volume 82, Issue 1, Pages (July 2012)

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

Volume 65, Issue 2, Pages 705-712 (February 2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation Armando Torres, Sagrario García, Angeles Gćmez, Antonieta González, Ysamar Barrios, María Teresa Concepción, Domingo Hernández, José J. García, María Dolores Checa, Victor Lorenzo, Eduardo Salido Kidney International Volume 65, Issue 2, Pages 705-712 (February 2004) DOI: 10.1111/j.1523-1755.2004.00432.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Changes of bone mineral density (BMD) at different regions 3 and 12months after transplantation, in the calcitriol and placebo groups. Values are adjusted for age, BMI, baseline BMD, and parathyroid hormone levels. Mean ± SE. Kidney International 2004 65, 705-712DOI: (10.1111/j.1523-1755.2004.00432.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Percent change of BMD 3months after transplantation as a function of vitamin D receptor (VDR) genotype and therapy group. Values are adjusted for age, BMI, baseline BMD, and PTH levels. P value is for the treatment by genotype interaction. Mean ± SE. Kidney International 2004 65, 705-712DOI: (10.1111/j.1523-1755.2004.00432.x) Copyright © 2004 International Society of Nephrology Terms and Conditions